Dario Publishes Two Peer-Reviewed Studies Demonstrating Impact Of Digital Behavioral Health
$DRIO
Medical/Dental Instruments
Health Care
Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens
Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2022 | $8.75 | Neutral → Buy | Alliance Global Partners |
| 1/26/2022 | $28.00 → $25.00 | Buy | Aegis Capital |
| 8/19/2021 | $35.00 → $28.00 | Buy | Aegis Capital |
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
Company to host conference call and webcast at 8:30am ET NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, November 7th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal
Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increaseCore B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring,
SC 13G - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK, Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025. Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025. The contracts s
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK, Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions. The launch with this new health plan marks the third Medicaid client for Dario, continuing a solid momentum within the Medicaid space. The newly signed health plan, familiar with Dario's results with another regional health plan, chose Dario based on the Company's success and reputation for
SCHEDULE 13G/A - DarioHealth Corp. (0001533998) (Subject)
10-Q - DarioHealth Corp. (0001533998) (Filer)
DEF 14A - DarioHealth Corp. (0001533998) (Filer)
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets
Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $28.00 from $35.00 previously
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi
Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand NEW YORK, April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms. Dario also